Dr. Chao H. Huang
Claim this profileUniversity of Kansas Health System Saint Francis Campus
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
31 drugs studied
About Chao H. Huang
Education:
- Completed preparatory studies at Colegio Rosario, Porto Alegre, Rio Grande do Sul.
- Earned an MD from Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul.
Experience:
- Completed an Internship and Residency in Internal Medicine at Presbyterian Medical Center of the University of Pennsylvania Health System, Philadelphia, PA.
- Undertook a Clinical Fellowship in Hematology & Medical Oncology at Fox Chase Cancer Center and Temple University Hospital.
- Actively involved in teaching and mentoring at the University of Kansas Health System Saint Francis Campus, specializing in lung cancer and head and neck cancer.
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Chao H. Huang is currently running
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
More about Chao H. Huang
Clinical Trial Related5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Chao H. Huang has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Nivolumab
- Docetaxel
- Selpercatinib
Breakdown of trials Chao H. Huang has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Recurrence
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chao H. Huang specialize in?
Chao H. Huang focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Chao H. Huang currently recruiting for clinical trials?
Yes, Chao H. Huang is currently recruiting for 8 clinical trials in Topeka Kansas. If you're interested in participating, you should apply.
Are there any treatments that Chao H. Huang has studied deeply?
Yes, Chao H. Huang has studied treatments such as Pembrolizumab, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Chao H. Huang?
Apply for one of the trials that Chao H. Huang is conducting.
What is the office address of Chao H. Huang?
The office of Chao H. Huang is located at: University of Kansas Health System Saint Francis Campus, Topeka, Kansas 66606 United States. This is the address for their practice at the University of Kansas Health System Saint Francis Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.